Viewray Stock Price, News & Analysis (NASDAQ:VRAY)

$8.31 +0.05 (+0.61 %)
(As of 02/23/2018 04:00 PM ET)
Previous Close$8.31
Today's Range$8.08 - $8.37
52-Week Range$4.40 - $10.64
Volume322,948 shs
Average Volume684,134 shs
Market Capitalization$565.34 million
P/E Ratio-7.35
Dividend YieldN/A
Beta-0.06

About Viewray (NASDAQ:VRAY)

Viewray logoViewRay, Inc. designs, manufactures and markets MRIdian, the magnetic resonance imaging (MRI)-guided radiation therapy system to image and treat cancer patients simultaneously. The Company offers radiation therapy technology combined with magnetic resonance imaging. MRIdian integrates MRI technology, radiation delivery and the Company's software to locate, target and track the position and shape of soft-tissue tumors while radiation is delivered. MRIdian delivers radiation to the tumor accurately while delivering less radiation to healthy tissue. MRIdian provides real-time imaging that defines the targeted tumor from the surrounding soft tissue and other critical organs during radiation treatment. MRIdian allows physicians to record the level of radiation exposure that the tumor has received and adapt the prescription between fractions as needed.

Receive VRAY News and Ratings via Email

Sign-up to receive the latest news and ratings for VRAY and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Advanced Medical Equipment & Technology
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:VRAY
CUSIPN/A
Phone14407033210

Debt

Debt-to-Equity Ratio-1.67%
Current Ratio1.59%
Quick Ratio1.20%

Price-To-Earnings

Trailing P/E Ratio-7.35398230088496
Forward P/E Ratio-7.91
P/E GrowthN/A

Sales & Book Value

Annual Sales$22.24 million
Price / Sales25.24
Cash FlowN/A
Price / CashN/A
Book Value($1.00) per share
Price / Book-8.31

Profitability

Trailing EPS($1.13)
Net Income$-50,630,000.00
Net Margins-193.53%
Return on EquityN/A
Return on Assets-59.34%

Miscellaneous

Employees92
Outstanding Shares67,540,000

Viewray (NASDAQ:VRAY) Frequently Asked Questions

What is Viewray's stock symbol?

Viewray trades on the NASDAQ under the ticker symbol "VRAY."

How were Viewray's earnings last quarter?

Viewray Inc (NASDAQ:VRAY) released its quarterly earnings results on Monday, November, 13th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.12) by $0.07. The company had revenue of $12.20 million for the quarter, compared to analysts' expectations of $18.63 million. The business's revenue was up 2950.0% on a year-over-year basis. View Viewray's Earnings History.

Where is Viewray's stock going? Where will Viewray's stock price be in 2018?

6 equities research analysts have issued 12 month price objectives for Viewray's shares. Their predictions range from $10.00 to $13.50. On average, they anticipate Viewray's stock price to reach $11.58 in the next twelve months. View Analyst Ratings for Viewray.

What are Wall Street analysts saying about Viewray stock?

Here are some recent quotes from research analysts about Viewray stock:

  • 1. Mizuho analysts commented, "We are not too concerned because the of usual lumpiness at the beginning of new operations. Management remains confident it can complete installation of 7-8 units before year-end. On the positive side, new orders received grew to $29.9 mil vs. our est. of $24.3 mil. Given the favorable development in Europe, Q4 back orders may exceed our expectations." (11/13/2017)
  • 2. Northland Securities analysts commented, "We are maintaining our FY17 & FY18 numbers, and our PT & ratings remain the same. Key Points Perhaps the most interesting takeaway from the call was the announcement of a multi-institutional trial on unresectable pancreatic cancer using MRIdian. It is our understanding that this trial will include both MRIdian Cobalt & LINAC (as they become available); will include a hard endpoint like survival, and possibly" intraop dose titration and impact on outcomes. As a reminder, most patients with pancreatic cancer will die within 1 – 2 years, with median survival @ 1-year. Hence, it is certainly possible that ViewRay could provide survival endpoints for such a trial in late 2018 / early 2019. This obviously is predicated on the trial design, sample size, inclusion criteria, and whether this will be randomized or not. The ideal design would obviously be to include a comparative arm with another RT machine (like the TruBeam) & compare to MRIdian. Finally, how outcomes will be influenced with the use of Cobalt vs. LINAC will also be interesting to note, although it might be hard to draw any statistical conclusions given small sample size." (5/16/2017)
  • 3. Aegis analysts commented, "We are assuming coverage of VRAY with a Buy rating and $11 PT. We believe the MRI-guided LINAC is a game-changer in radiation oncology, with real-time imaging improving dosimetry and reducing the toxicity to patients. The combination improves functionality and expands the use of stereotactic body radiation therapy (SBRT), and physicians believe the system can expand the total treatable tumors by at least 20%." (5/16/2017)

Who are some of Viewray's key competitors?

When did Viewray IPO?

(VRAY) raised $52 million in an initial public offering on the week of April 6th 2015. The company issued 4,000,000 shares at $12.00-$14.00 per share. Cowen and Company and Stifel served as the underwriters for the IPO and BTIG and Brean Capital were co-managers.

Who owns Viewray stock?

Viewray's stock is owned by many different of institutional and retail investors. Top institutional investors include Park West Asset Management LLC (3.87%), BlackRock Inc. (2.74%), RTW Investments LP (2.00%), Sectoral Asset Management Inc (1.40%), Citadel Advisors LLC (0.99%) and Next Century Growth Investors LLC (0.88%). Company insiders that own Viewray stock include Aditya Puri, Ajay Bansal, David P Bonita, Fmr Llc and Henry A Mckinnell. View Institutional Ownership Trends for Viewray.

Who sold Viewray stock? Who is selling Viewray stock?

Viewray's stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Falcon Point Capital LLC, TIAA CREF Investment Management LLC, Raymond James & Associates and Next Century Growth Investors LLC. View Insider Buying and Selling for Viewray.

Who bought Viewray stock? Who is buying Viewray stock?

Viewray's stock was bought by a variety of institutional investors in the last quarter, including Park West Asset Management LLC, Sectoral Asset Management Inc, Citadel Advisors LLC, EAM Investors LLC, RTW Investments LP, BlackRock Inc., Bank of New York Mellon Corp and Perceptive Advisors LLC. Company insiders that have bought Viewray stock in the last two years include Aditya Puri, Ajay Bansal, David P Bonita and Henry A Mckinnell. View Insider Buying and Selling for Viewray.

How do I buy Viewray stock?

Shares of Viewray can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Viewray's stock price today?

One share of Viewray stock can currently be purchased for approximately $8.31.

How big of a company is Viewray?

Viewray has a market capitalization of $565.34 million and generates $22.24 million in revenue each year. The company earns $-50,630,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis. Viewray employs 92 workers across the globe.

How can I contact Viewray?

Viewray's mailing address is 2 THERMO FISHER WAY, OAKWOOD VILLAGE OH, 44146. The company can be reached via phone at 14407033210 or via email at [email protected]


MarketBeat Community Rating for Viewray (VRAY)

Community Ranking:  3.1 out of 5 (star star star)
Outperform Votes:  101 (Vote Outperform)
Underperform Votes:  60 (Vote Underperform)
Total Votes:  161
MarketBeat's community ratings are surveys of what our community members think about Viewray and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Viewray (NASDAQ:VRAY) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $11.58$11.20$10.60$9.50
Price Target Upside: 41.61% upside24.58% upside12.41% upside83.75% upside

Viewray (NASDAQ:VRAY) Consensus Price Target History

Price Target History for Viewray (NASDAQ:VRAY)

Viewray (NASDAQ:VRAY) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/8/2018B. RileyInitiated CoverageBuy -> Buy$13.50LowView Rating Details
1/9/2018MizuhoReiterated RatingBuy$12.00MediumView Rating Details
1/8/2018Cantor FitzgeraldSet Price TargetBuy$13.00MediumView Rating Details
11/17/2017Northland SecuritiesReiterated RatingBuy$10.00N/AView Rating Details
7/22/2017AegisReiterated RatingBuy$11.00HighView Rating Details
5/17/2017BTIG ResearchReiterated RatingBuy$10.00MediumView Rating Details
(Data available from 2/23/2016 forward)

Earnings

Viewray (NASDAQ:VRAY) Earnings History and Estimates Chart

Earnings by Quarter for Viewray (NASDAQ:VRAY)

Viewray (NASDAQ VRAY) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017Q3 2017($0.12)($0.19)$18.63 million$12.20 millionViewN/AView Earnings Details
8/7/2017Q2 2017($0.24)($0.26)$0.68 million$0.70 millionViewListenView Earnings Details
5/15/2017Q1 2017($0.22)($0.24)$0.52 million$1.23 millionViewN/AView Earnings Details
3/16/2017Q4 2016($0.34)($0.25)$13.65 million$16.13 millionViewN/AView Earnings Details
11/14/2016Q316($0.27)($0.35)$0.39 million$0.36 millionViewN/AView Earnings Details
8/15/2016Q216($0.29)($0.32)$5.53 million$0.30 millionViewListenView Earnings Details
5/13/2016Q116($0.30)($0.35)$5.50 million$5.50 millionViewN/AView Earnings Details
3/28/2016Q4 2015($0.37)$4.61 millionViewN/AView Earnings Details
11/9/2015Q3 2015($0.35)$5.32 millionViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Viewray (NASDAQ:VRAY) Earnings Estimates

2018 EPS Consensus Estimate: ($0.81)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.22)($0.22)($0.22)
Q2 20181($0.21)($0.21)($0.21)
Q3 20181($0.19)($0.19)($0.19)
Q4 20181($0.19)($0.19)($0.19)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Viewray (NASDAQ:VRAY)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Viewray (NASDAQ VRAY) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 62.81%
Institutional Ownership Percentage: 51.24%
Insider Trades by Quarter for Viewray (NASDAQ:VRAY)
Institutional Ownership by Quarter for Viewray (NASDAQ:VRAY)

Viewray (NASDAQ VRAY) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/25/2017Fmr LlcInsiderSell106,781$6.76$721,839.56View SEC Filing  
4/24/2017Fmr LlcInsiderSell101,139$6.71$678,642.69View SEC Filing  
4/20/2017Fmr LlcInsiderSell101,236$6.90$698,528.40View SEC Filing  
4/18/2017Fmr LlcInsiderSell107,217$7.24$776,251.08View SEC Filing  
4/13/2017Fmr LlcInsiderSell115,860$7.44$861,998.40View SEC Filing  
4/12/2017Fmr LlcInsiderSell179,494$7.40$1,328,255.60View SEC Filing  
4/10/2017Fmr LlcInsiderSell178,556$7.77$1,387,380.12View SEC Filing  
4/7/2017Fmr LlcInsiderSell52,050$7.89$410,674.50View SEC Filing  
4/5/2017Fmr LlcInsiderSell196,397$7.90$1,551,536.30View SEC Filing  
4/3/2017Fmr LlcInsiderSell217,883$8.29$1,806,250.07View SEC Filing  
3/30/2017Fmr LlcInsiderSell28,661$8.46$242,472.06View SEC Filing  
1/18/2017Ajay BansalCFOBuy62,597$3.17$198,432.4970,104View SEC Filing  
1/18/2017Henry A. MckinnellDirectorBuy312,989$3.17$992,175.13View SEC Filing  
9/9/2016Aditya PuriDirectorBuy1,472,803$2.95$4,344,768.8518,964View SEC Filing  
8/22/2016David P BonitaDirectorBuy1,138,074$2.95$3,357,318.30View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Viewray (NASDAQ VRAY) News Headlines

Source:
DateHeadline
Viewray (VRAY) vs. Waters (WAT) Critical ContrastViewray (VRAY) vs. Waters (WAT) Critical Contrast
www.americanbankingnews.com - February 19 at 3:16 PM
BIOLASE (BIOL) and Viewray (VRAY) Head to Head ContrastBIOLASE (BIOL) and Viewray (VRAY) Head to Head Contrast
www.americanbankingnews.com - February 18 at 1:44 PM
Viewray (VRAY) Stock Rating Lowered by BidaskClubViewray (VRAY) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - February 18 at 1:00 PM
$20.09 Million in Sales Expected for Viewray Inc (VRAY) This Quarter$20.09 Million in Sales Expected for Viewray Inc (VRAY) This Quarter
www.americanbankingnews.com - February 16 at 5:34 AM
Viewray Inc (VRAY) to Post FY2017 Earnings of ($1.08) Per Share, B. Riley ForecastsViewray Inc (VRAY) to Post FY2017 Earnings of ($1.08) Per Share, B. Riley Forecasts
www.americanbankingnews.com - February 12 at 1:08 AM
Viewray (VRAY) Now Covered by Analysts at B. RileyViewray (VRAY) Now Covered by Analysts at B. Riley
www.americanbankingnews.com - February 11 at 3:24 PM
Viewray Inc (VRAY) Receives Consensus Recommendation of "Buy" from AnalystsViewray Inc (VRAY) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - February 10 at 7:50 AM
ViewRay Appoints Scott Huennekens and Daniel Moore to its Board of DirectorsViewRay Appoints Scott Huennekens and Daniel Moore to its Board of Directors
finance.yahoo.com - February 8 at 7:22 AM
FY2017 Earnings Estimate for Viewray Inc (VRAY) Issued By Cantor FitzgeraldFY2017 Earnings Estimate for Viewray Inc (VRAY) Issued By Cantor Fitzgerald
www.americanbankingnews.com - January 31 at 8:32 AM
Viewray Inc (VRAY) Expected to Announce Quarterly Sales of $20.42 MillionViewray Inc (VRAY) Expected to Announce Quarterly Sales of $20.42 Million
www.americanbankingnews.com - January 30 at 6:16 AM
Zacks: Brokerages Anticipate Viewray Inc (VRAY) to Announce -$0.29 Earnings Per ShareZacks: Brokerages Anticipate Viewray Inc (VRAY) to Announce -$0.29 Earnings Per Share
www.americanbankingnews.com - January 28 at 11:16 AM
Morning Technical Insight on These Medical Equipment Stocks -- ReWalk Robotics, Avinger, ViewRay, and Align TechnologyMorning Technical Insight on These Medical Equipment Stocks -- ReWalk Robotics, Avinger, ViewRay, and Align Technology
www.bizjournals.com - January 26 at 7:29 AM
Viewray (VRAY) versus GenMark Diagnostics (GNMK) Head-To-Head SurveyViewray (VRAY) versus GenMark Diagnostics (GNMK) Head-To-Head Survey
www.americanbankingnews.com - January 21 at 5:26 AM
FY2017 EPS Estimates for Viewray Inc (VRAY) Decreased by AnalystFY2017 EPS Estimates for Viewray Inc (VRAY) Decreased by Analyst
www.americanbankingnews.com - January 19 at 10:08 AM
Viewray Inc to Post FY2019 Earnings of $0.31 Per Share, Zacks Investment Research Forecasts (VRAY)Viewray Inc to Post FY2019 Earnings of $0.31 Per Share, Zacks Investment Research Forecasts (VRAY)
www.americanbankingnews.com - January 18 at 9:04 PM
Viewray (VRAY) vs. Pacific Biosciences of California (PACB) Head to Head ReviewViewray (VRAY) vs. Pacific Biosciences of California (PACB) Head to Head Review
www.americanbankingnews.com - January 18 at 3:30 PM
Head to Head Survey: Viewray (VRAY) & Pacific Biosciences of California (PACB)Head to Head Survey: Viewray (VRAY) & Pacific Biosciences of California (PACB)
www.americanbankingnews.com - January 17 at 3:12 AM
VRAY: 2017 Financial Highlights. What To Expect In 2018VRAY: 2017 Financial Highlights. What To Expect In 2018
finance.yahoo.com - January 16 at 4:20 PM
Viewray Inc (VRAY) Receives Average Rating of "Buy" from AnalystsViewray Inc (VRAY) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - January 16 at 8:32 AM
Viewray Sees Unusually High Options Volume (VRAY)Viewray Sees Unusually High Options Volume (VRAY)
www.americanbankingnews.com - January 12 at 1:28 AM
 Analysts Expect Viewray Inc (VRAY) Will Post Earnings of -$0.15 Per Share Analysts Expect Viewray Inc (VRAY) Will Post Earnings of -$0.15 Per Share
www.americanbankingnews.com - January 11 at 11:41 AM
Brokers Offer Predictions for Viewray Incs FY2017 Earnings (VRAY)Brokers Offer Predictions for Viewray Inc's FY2017 Earnings (VRAY)
www.americanbankingnews.com - January 10 at 6:30 AM
ViewRay (VRAY) Reports Prelim 4Q & FY17 Revenues Above ConsensusViewRay (VRAY) Reports Prelim 4Q & FY17 Revenues Above Consensus
www.streetinsider.com - January 8 at 4:27 PM
ViewRay Announces Preliminary Fourth Quarter and Fiscal Year 2017 ResultsViewRay Announces Preliminary Fourth Quarter and Fiscal Year 2017 Results
finance.yahoo.com - January 8 at 10:47 AM
Investors Buy High Volume of Viewray Call Options (VRAY)Investors Buy High Volume of Viewray Call Options (VRAY)
www.americanbankingnews.com - January 7 at 2:40 AM
Viewray (VRAY) Rating Reiterated by Cantor FitzgeraldViewray (VRAY) Rating Reiterated by Cantor Fitzgerald
www.americanbankingnews.com - January 6 at 11:10 PM
Pre-Open Movers 01/05: (CNIT) (DWCH) (FC) Higher; (OHRP) (RGNX) (FRAN) Lower (more...)Pre-Open Movers 01/05: (CNIT) (DWCH) (FC) Higher; (OHRP) (RGNX) (FRAN) Lower (more...)
www.streetinsider.com - January 5 at 10:48 AM
-$0.15 EPS Expected for Viewray Inc (VRAY) This Quarter-$0.15 EPS Expected for Viewray Inc (VRAY) This Quarter
www.americanbankingnews.com - December 26 at 1:08 AM
Viewray (VRAY) Stock Rating Upgraded by BidaskClubViewray (VRAY) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - December 22 at 1:02 PM
Viewray Inc (VRAY) Given Average Rating of "Buy" by AnalystsViewray Inc (VRAY) Given Average Rating of "Buy" by Analysts
www.americanbankingnews.com - December 22 at 8:58 AM
Oncology Experts to Convene for Symposium to Advance MR Image-Guided Radiation TherapyOncology Experts to Convene for Symposium to Advance MR Image-Guided Radiation Therapy
finance.yahoo.com - December 19 at 10:39 AM
ViewRay Inc (NASDAQ:VRAY): Does 20.2% EPS Decline Lately Make It An Underperformer?ViewRay Inc (NASDAQ:VRAY): Does 20.2% EPS Decline Lately Make It An Underperformer?
finance.yahoo.com - December 15 at 11:03 AM
ETFs with exposure to ViewRay, Inc. : December 11, 2017ETFs with exposure to ViewRay, Inc. : December 11, 2017
finance.yahoo.com - December 11 at 4:29 PM
$29.68 Million in Sales Expected for Viewray Inc (VRAY) This Quarter$29.68 Million in Sales Expected for Viewray Inc (VRAY) This Quarter
www.americanbankingnews.com - December 10 at 9:54 AM
ViewRay (VRAY) Downgraded by BidaskClub to HoldViewRay (VRAY) Downgraded by BidaskClub to Hold
www.americanbankingnews.com - December 9 at 6:22 AM
Zacks: Analysts Anticipate ViewRay, Inc. (VRAY) Will Announce Earnings of -$0.15 Per ShareZacks: Analysts Anticipate ViewRay, Inc. (VRAY) Will Announce Earnings of -$0.15 Per Share
www.americanbankingnews.com - December 8 at 8:06 AM
ViewRay (VRAY) Lowered to "Sell" at ValuEngineViewRay (VRAY) Lowered to "Sell" at ValuEngine
www.americanbankingnews.com - December 2 at 12:40 AM
ETFs with exposure to ViewRay, Inc. : November 30, 2017ETFs with exposure to ViewRay, Inc. : November 30, 2017
finance.yahoo.com - November 30 at 4:20 PM
ViewRay, Inc. :VRAY-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017ViewRay, Inc. :VRAY-US: Earnings Analysis: Q3, 2017 By the Numbers : November 29, 2017
finance.yahoo.com - November 29 at 10:43 AM
ViewRay, Inc. (VRAY) Receives Consensus Rating of "Buy" from AnalystsViewRay, Inc. (VRAY) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - November 27 at 7:46 AM
Financial Review: ViewRay (VRAY) vs. Presbia PLC (LENS)Financial Review: ViewRay (VRAY) vs. Presbia PLC (LENS)
www.americanbankingnews.com - November 22 at 7:14 PM
ViewRay® to Participate in Upcoming ConferencesViewRay® to Participate in Upcoming Conferences
finance.yahoo.com - November 22 at 5:28 PM
ViewRay, Inc. (VRAY) Expected to Announce Quarterly Sales of $29.68 MillionViewRay, Inc. (VRAY) Expected to Announce Quarterly Sales of $29.68 Million
www.americanbankingnews.com - November 22 at 8:17 AM
ViewRay, Inc. to Post FY2017 Earnings of ($0.88) Per Share, Zacks Investment Research Forecasts (VRAY)ViewRay, Inc. to Post FY2017 Earnings of ($0.88) Per Share, Zacks Investment Research Forecasts (VRAY)
www.americanbankingnews.com - November 22 at 5:52 AM
VRAY: Financial Results For Third Quarter 2017. Revising Revenue GuidanceVRAY: Financial Results For Third Quarter 2017. Revising Revenue Guidance
finance.yahoo.com - November 20 at 3:59 PM
ViewRay, Inc. (VRAY) Expected to Announce Earnings of -$0.10 Per ShareViewRay, Inc. (VRAY) Expected to Announce Earnings of -$0.10 Per Share
www.americanbankingnews.com - November 20 at 11:46 AM
ViewRays (VRAY) "Buy" Rating Reaffirmed at Northland SecuritiesViewRay's (VRAY) "Buy" Rating Reaffirmed at Northland Securities
www.americanbankingnews.com - November 18 at 5:36 PM
Why ViewRay, Inc. Jumped TodayWhy ViewRay, Inc. Jumped Today
finance.yahoo.com - November 18 at 10:08 AM
Comparing Thermo Fisher Scientific (TMO) and ViewRay (VRAY)Comparing Thermo Fisher Scientific (TMO) and ViewRay (VRAY)
www.americanbankingnews.com - November 14 at 3:39 PM
Edited Transcript of VRAY earnings conference call or presentation 13-Nov-17 1:30pm GMTEdited Transcript of VRAY earnings conference call or presentation 13-Nov-17 1:30pm GMT
finance.yahoo.com - November 13 at 9:44 PM

SEC Filings

Viewray (NASDAQ:VRAY) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Financials are not available for this stock.

Chart

Viewray (NASDAQ VRAY) Stock Chart for Friday, February, 23, 2018

Loading chart…

This page was last updated on 2/23/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.